Saltar al contenido
PivotalWire
Domingo 22 nov 2026SEC · NASDAQ biomédico

Calendario›CLRB›I-131-CLR1404

I-131-CLR1404

Ensayo de Cellectar Biosciences, Inc. en Cáncer.

Más ensayos de: Cáncer.

Fase
Fase 1
Estado
Completado
Participantes
12
previstos
Centros
3
Fin del objetivo primario
nov 2013
fecha real

Título oficial en el registro (en inglés): Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned

Qué significa cada fase y cada estado.

Estudio de intervención, de un solo grupo, abierto. Comenzó en dic 2011.

De principio a fin

  1. Empieza el ensayo (dic 2011)
  2. Lectura de resultados nov 2013 (real)
  3. Hoy

Los cambios los anota PivotalWire desde agosto de 2026; lo anterior no lo tenemos. El historial completo, versión a versión, está en ClinicalTrials.gov.

Qué mide

Determination of the recommended dose of I-131-CLR1404 in treating subjects with relapsed or refractory advanced solid malignancies (Until non-tolerated dose is defined; dose escalation descision made upon review of data from a complete cohort (56 days after all subjects in cohort have received therapy infusion)) (del registro, en inglés)

Qué se prueba

El ensayo busca determinar la dosis recomendada de I-131-CLR1404, un compuesto de terapia radiactiva, para tratar a personas con cáncer que no responde al tratamiento o ha vuelto.

Lo que dice el documentoThe purpose of this study is to determine the recommended dose of I-131-CLR1404, a radiolabeled therapy compound, for treating subjects with cancer that does not respond to treatment or has returned. The identified recommended dose in this study will be used as the optimal dose of I-131-CLR1404 in subsequent clinical trials conducted for later phase clinical development.

Traducción automática (claude-haiku-5-5). Lo comprobado es la cita: está literal en el documento y sus cifras cuadran con las de la frase. Todavía no la ha leído una persona.

Cómo lo describe el promotor

En el documentoEn inglés, del registroThe purpose of this study is to determine the recommended dose of I-131-CLR1404, a radiolabeled therapy compound, for treating subjects with cancer that does not respond to treatment or has returned. The identified recommended dose in this study will be used as the optimal dose of I-131-CLR1404 in subsequent clinical trials conducted for later phase clinical development. Subjects who meet study entry criteria will receive I-131-CLR1404. For each subject, the study will be conducted in two phases, dosimetric and therapy. In the dosimetric phase, subjects will receive one 5 mCi dose of the study drug and undergo whole body imaging on on the day of infusion and on post-infusion days 1, 2, 3, and 6 for assessment of biodistribution of I-131-CLR1404. If normal and expected biodistribution are demonstrated, the subject will begin the therapy phase. In the therapy phase, the first cohort of subjects will receive a dose of 12.5 mCi/m2. Dose escalation in subsequent cohorts will initially be in increments of 12.5 mCi/m2. Subjects will be followed and observed for unacceptable toxicity through 56 days after the therapy dose infusion with follow-up for up to one year. All subjects will be prescribed thyroid protection medication to be taken 24 hours prior to injection of the dosimetric dose, and continuing for 14 days after the administration of the therapy dose.

Más ensayos de CLRB

EnsayoFaseEstadoLectura de resultados
Iopofosine I 131 single dose · CLOVER-WaMFase 2En marcha, sin reclutarjun 2026 (prevista, ya pasada: sin actualizar en el registro)
CLR 131 · CLOVER-2Fase 1En marcha, sin reclutarjun 2027 (prevista)
CLR 131Fase 1En marcha, sin reclutarjun 2027 (prevista)
Iopofosine I 131Fase 1Reclutando pacientesfeb 2028 (prevista)
Iopofosine I 131Fase 3Aún sin reclutarene 2032 (prevista)
I-131-CLR1404Fase 1Completadodic 2020 (real)

Todos los de CLRB, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT01495663), actualizada en feb 2015.